Update shared on25 Sep 2025
Fair value Decreased 3.00%Evonik Industries' consensus price target has been reduced from €20.49 to €19.88 as analysts factor in increased downside risks to earnings, moderating growth expectations, persistent margin concerns, and industry headwinds, prompting greater near-term caution.
Analyst Commentary
- Bearish analysts highlight increased downside risks to earnings estimates due to both cyclical and structural pressures facing the company.
- Bullish analysts remain constructive but have trimmed price targets, implying reduced near-term upside amid market headwinds.
- Reduced price targets reflect moderating growth expectations and slower recovery assumptions in key end markets.
- Concerns persist around the sustainability of margin improvement initiatives amidst a challenging macroeconomic environment.
- While long-term fundamentals remain intact for some, consensus shifts suggest near-term caution due to industry and company-specific uncertainties.
What's in the News
- Evonik and Ethris have formed a strategic collaboration to develop and commercialize a novel lipid nanoparticle (LNP) platform for nucleic acid delivery, focusing on mRNA lung therapies.
- The partnership combines Evonik's formulation and clinical manufacturing expertise with Ethris' proprietary SNaP LNP technology, offering improved stability and targeted delivery, including for respiratory diseases via nebulized administration.
- The Ethris platform has demonstrated no systemic bioavailability of mRNA or protein in clinical trials, reducing off-target risks, and their lead asthma product is in Phase 2a trials.
Valuation Changes
Summary of Valuation Changes for Evonik Industries
- The Consensus Analyst Price Target has fallen slightly from €20.49 to €19.88.
- The Consensus Revenue Growth forecasts for Evonik Industries has significantly fallen from 1.1% per annum to 0.9% per annum.
- The Net Profit Margin for Evonik Industries has fallen from 5.13% to 4.82%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.